Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ESH ALL 2021 | Upcoming trial updates in ALL

David Marks • 4 May 2021

ESH ALL 2021

Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Imatinib Ponatinib

David Marks, MBBS, PhD, FRACP, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, shares upcoming promising clinical trials in the acute lymphoblastic leukemia (ALL) space. The use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lymphoblasts, is being evaluated in a randomized trial, and results are awaited with interest. Clinical trials comparing ponatinib and imatinib in Philadelphia chromosome-positive (Ph+) ALL will determine whether ponatinib is a superior treatment agent for Ph+ ALL. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.

The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL

David Marks • 24 Apr 2023

UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL

David Marks • 24 Apr 2023

The importance of MRD assessment before alloSCT in ALL

David Marks • 24 Apr 2023

Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy

David Marks • 24 May 2023

Related Videos

Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens

Christina Peters • 15 Apr 2024

Promising novel agents in AML: menin inhibitors

Mark Levis • 16 Apr 2024

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation

Valentin Ortiz-Maldonado • 16 Apr 2024

Do all patients require maintenance therapy following alloSCT?

Mark Levis • 16 Apr 2024